阿里云企航提供域名产品、网站建设、商标软著、资质备案、案例库和移动端服务。

阿里云企航

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Metric
Company Name	阿里云企航	Protagonist Therapeutics, Inc.
Symbol		PTGX
MSH ID	COM:DACBIOTECH	COM:PROTAGONIST-INC
Market	PRIVATE	STOCKS
Sector	Technology	Healthcare
Industry	Cloud Computing and Internet Services	Biotechnology
Country	CN	US
Stage		Post-IPO Equity
Employee Count		124
Website	dacbiotech.com	protagonist-inc.com
LinkedIn
Founders

Metric
Market Cap		2.04B
Enterprise Value
Monthly Web Traffic		3.14K
Web Traffic Growth		0.28
Valuation
Raised Capital		132.20M

Metric
Revenue		60M
Revenue (LTM)
Revenue (NTM)
Gross Profit		56.69M
EBITDA		-90.34M
Operating Income		-93.65M
Net Income		-78.95M
EPS		-1.39
Diluted EPS		-1.39
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.99
Operating Profit Margin		0.48
EBITDA Margin		-1.51
Net Profit Margin		0.53
Return on Equity		1.18
Return on Assets		0.28
Return on Capital Employed		0.27

COM:DACBIOTECH

阿里云企航

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-11.44
P/B Ratio		-2.41
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		27.34
EV Multiple		20.49

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding		0.00
Operating Cycle		348.14
Cash Conversion Cycle		-22.23
Asset Turnover		0.52

Metric
Operating Cash Flow		-70.24M
Free Cash Flow		-70.84M
Cash Flow to Debt		17.00
Operating Cash Flow/Sales		0.73
Free Cash Flow Yield		-0.08

Metric
Cash & Equivalents		186.73M
Accounts Receivable		-9.99M
Inventory		-10.33M
Goodwill
Debt to Capitalization		0.02
Debt to Assets		0.01
Current Ratio		11.66
Quick Ratio		16.54

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue